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Abstract 
Both graying and melanoma formation in horses have recently been linked to a 
duplication in the syntaxin-17 (STX17) gene. This duplication, as well as a mutation in 
the agouti signaling protein (ASIP) gene that increases melanocortin-1-receptor (MC1R) 
pathway signaling, affect melanoma risk and severity in gray horses.  
We hypothesized that melanoma susceptibility in gray Quarter Horses (QH) is 
lower than gray horses from other breeds, and that this might be due to decreased MC1R 
signaling resulting from a high incidence of the MC1R chestnut coat color allele in the 
QH population. 
Blood or hair root samples were collected from 335 gray QH with and without 
dermal melanomas, for DNA extraction and genotyping for STX17, ASIP and MC1R 
genes.  Age, gender and external melanoma presence and grade were recorded. The effect 
of age and genotype on melanoma presence and severity was evaluated by candidate gene 
association study.   
The melanoma prevalence and grade in this QH cohort were lower than in other 
breeds. Age was significantly associated with melanoma prevalence and severity. No 
significant effect of MC1R genotype on melanoma prevalence or severity was identified. 
In contrast to prior reports, an effect of ASIP genotype on both melanoma prevalence and 
grade was not detected. Homozygosity of STX17 was low and precluded evaluation of the 
gray allele effect on melanoma presence and severity.   
Melanoma prevalence and severity appears to be lower in gray QH than in other 
breeds. This could be due to infrequent STX17 homozygosity, a mitigating effect of the 
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MC1R mutation on ASIP potentiation of melanoma, other genes in the MC1R signaling 
pathway, or differences in breed genetic background. 
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Melanomas are primary tumors of melanocytes and account for 15% of equine skin 
tumors1. Equine melanomas are classified into 4 groups according to clinical and 
histopathologic features: melanocytic nevi, anaplastic malignant melanoma, dermal 
melanoma and dermal melanomatosis 2. Melanocytic nevi and anaplastic malignant 
melanoma affect horses of any age, breed or coat color 2. In contrast, dermal melanoma and 
dermal melanomatosis occur primarily on the glabrous skin of the ventral tail, perineum, 
external genitalia, lips and eyelids of gray horses 3, 4. Dermal melanoma and dermal 
melanomatosis are distinguished clinically by the number of masses and the presence of 
metastasis, but are not distinguishable histopathologically and may represent a clinical 
continuum 2, 3.  
Up to 80% of gray horses older than 15 years develop melanomas 1,13 and 14% to 66% 
of dermal melanomas eventually metastasize 4,3. All dermal melanomas should be considered 
potentially malignant since histopathologic changes and location cannot predict the risk of 
metastasis 4. Melanoma therapy is more effective when instituted early in the course of 
disease. Therapeutic options include surgical excision, intralesional cisplatin injections, 
intralesional cisplatin beads, systemic cimetidine or autologous vaccine. When the tumors 
become enlarged, locally invasive or metastatic, therapy is usually not feasible 4,11,12,15.  
Therefore, early identification of the animals that are at greater risk of developing melanomas 
is necessary. A better understanding of the risk factors involved in melanoma susceptibility, 
severity and the risk of metastasis may allow for better prediction of tumor behavior and 
allow early intervention in horses that are more likely to develop severe, life threatening 
consequences to dermal melanomas, before therapy options are limited.    
   3 
 
STX17 duplication, gray coat color, and increased melanoma risk  
 
 
 Graying and melanoma have recently been linked to a 4.6 kilobase (kb) duplication 
in intron 6 of the syntaxin-17 (STX17) gene5. This duplication is found in a non-coding 
segment of DNA; however this region harbors a regulatory element containing two 
microphthalmia-associated transcription factor (MITF) binding sites, and a NGFI-B-
response element (NBRE).  Both MITF and NRBE play a role in pigmentation; MITF 
enhances melanocyte production and survival and controls melanin production within 
melanocytes, and NRBE serves as a binding site for NR4A3 which is a key component of 
the melanocortin-1-receptor signaling pathway (Figure 1). Studies in transgenic zebrafish 
have demonstrated that this regulatory element drives reporter gene expression in the 
mitfa-expressing neural crest cells that become melanoblasts, and eventually skin and hair 
follicle melanocytes 6. Studies in transgenic zebrafish with an analogous duplication (i.e. 
similar to horses with the gray mutation) have demonstrated that this regulatory element 
drives a significantly higher level of reporter gene expression in melanoblasts and skin 
melanocytes than zebrafish with a single copy “wild-type” construct 6. MITF is necessary 
for the expression of STX17 6, and both STX17 and its neighboring gene NR4A3, are up-
regulated in melanomas from gray horses 5. Taken together these data suggest that the 
duplicated region is a melanocyte-specific, cis-acting regulatory element for both STX17 
and NR4A3.  
 It has been hypothesized that duplication of the regulatory elements in STX17 
results in up-regulation of melanin production and proliferation of hair follicle and 
dermal/epidermal melanocytes and is the link between the STX17 duplication, gray coat 
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color and melanoma formation 5, 6. The hair follicle melanocytes responsible for melanin 
production and hair pigmentation are recruited from melanocyte stem cells at the base of 
the follicle and undergo apoptosis at the end of each hair cycle. Up-regulation and/or 
increased recruitment of hair follicle melanocytes in horses with the STX17 mutation 
leads to increased hair follicle melanin production early in life, resulting in a dark coat 
color 5. With age, the melanocyte stem cell pool becomes depleted resulting in a loss of 
hair pigmentation and progressive graying. Horses homozygous (GG) for the STX17 
mutation show more rapid graying, more frequent vitiligo (loss of skin pigmentation, 
Figure 2), little to no speckling (Figure 2) and are more homogenously white in the final 
stage of the graying process than horses heterozygous (Gg) for the duplication 5.  
 In contrast to follicular melanocytes, the dermal and epidermal melanocytes in 
glabrous skin (skin without hair) do not undergo apoptosis at the end of the hair cycle 5. 
MITF regulated proliferation of skin melanocytes, may predispose horses to melanoma 
formation; and MITF has been identified as a melanoma oncogene in humans24. Further, 
up-regulation of NR4A3 has been associated with carcinogenesis in humans25. Horses 
which are homozygous gray, and thus have two copies of the duplication have a higher 
melanoma incidence and higher mean melanoma grade than horse that are heterozygous 
gray (one copy of the duplication)5, consistent with increased MITF and NR4A3 mediated 
regulation of melanocyte behavior. NR4A3 mRNA levels, and the mRNA levels of its 
downstream target CCND2 are both elevated in equine dermal melanoma, suggesting a 
key role for this pathway in melanoma development 5.   
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Melanocortin-1-receptor signaling, coat color mutations and melanoma  
 
 
 Signaling through the melanocortin-1-receptor (MC1R) is the primary pathway 
regulating melanin synthesis in melanocytes (Figure 1). Signaling through MC1R and its 
regulation by agouti signaling protein (ASIP) determines the amount of eumelanin (black 
pigment) and pheomelanin (red/orange pigment) produced by melanocytes, and the 
pattern of eumelanin distribution responsible for the basic coat colors. In horses, a 
mutation in the MC1R gene results in decreased MC1R signaling, and horses that are 
homozygous for the mutation (MC1R e/e), have a switch from eumelanin to pheomelanin 
production resulting in production of red pigment and the chestnut coat color 8. Horses 
carrying a wild-type MC1R gene (MC1R E/e, E/E) produce eumelanin instead of 
pheomelanin, resulting in the bay/brown or black phenotype 7. ASIP normally 
antagonizes MC1R and decreases signaling through the receptor. However, a mutation in 
the ASIP gene results in a loss of ASIP antagonistic function and a relative increase in 
MC1R signaling. In the presence of wild-type MC1R gene, horses homozygous for the 
ASIP mutation (MC1RE_ ASIP a/a), have an even distribution of eumelanin and black coat 
color versus the bay/brown phenotype (MC1RE_ ASIP A/a, A/A) 7. In horses that are 
homozygous for the MC1R mutation (MC1R e/e), ASIP genotype has no effect on coat 
color as eumelanin is not produced, thus chestnut coat color is epistatic over 
bay/black/brown 8.   
 Gray is epistatic to all other coat colors, so horses with the STX17 duplication turn 
gray with age, regardless of their other coat color genotypes 26. However, gray horses still 
have MC1R signaling in dermal and epidermal melanocytes even after the hair follicle 
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melanocytes have been depleted. Thus, genotypes at MC1R and ASIP still regulate MC1R 
signaling even though the effect on coat color is no longer phenotypically present. 
Transcription of both NR4A3 and MITF, the link between STX17 and melanoma, are 
mediated by signaling through MC1R; thus alterations in this signaling pathway have the 
potential to impact melanoma phenotype. The relative increase in MC1R signaling 
associated with the ASIPa allele has been linked to increased melanoma prevalence and 
melanoma grade in gray horses 5. It is important to note however, that the effect of the 
ASIPa allele on melanoma grade is additive, whereas the effect of the ASIPa on coat color 
is recessive. Thus while the increase in MC1R signaling in ASIPAa heterozygotes is not 
sufficient to alter coat color; it is enough to increase melanoma risk and severity.  
A loss of function mutation in the MC1R gene results in the “chestnut” coat color in 
horses8. This mutation, by decreasing melanocyte cAMP levels, also has the potential to 
affect melanoma formation and severity in gray horses through the downstream effect of 
decreased MITF and NR4A3 transcription (Figure 1)9. In humans, similar MC1R variants 
which alter MITF expression have been linked to better outcomes in melanoma 
patients10.  
The impact of altered MC1R signaling associated with the MC1R mutation on 
melanoma development and severity in horses has not been evaluated.  In this study, we 
evaluate melanoma prevalence and severity in a population of greater than 300 gray 
Quarter Horses (QH), and the effects of genotypes at the STX17, ASIP, and MC1R loci on 
melanoma prevalence and severity. Since therapies for equine melanomas are most 
effective when they are initiated early, prior to extensive invasion of local tissue or 
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metastasis, early identification of the animals that are at greater risk of developing severe 
melanomas is necessary.  
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Figure 1. Role of STX17 and MC1R signaling in melanoma formation.  
 
Normal MC1R signaling (black boxes/arrows): MC1R signaling is activated by the binding of the agonists α –MSH 
or ACTH to the MC1R receptor. Activation of MC1R results in increased cellular cyclic-AMP (cAMP) levels (a) 
which results in increased MITF expression (b) leading to increased melanin synthesis (c); stimulation of tyrosinase 
leading to eumelanin (black/brown) pigment production (d); and increased NR4A3 transcription (e) which mediates 
cell cycle and proliferation through the action of CCND2 (f). Normal ASIP (brown boxes/arrows) antagonizes the 
MC1R receptor resulting in a decrease in MC1R signaling and decreased eumelanin production (g) leading to the 
wild-type bay/brown coat color (in horses with at wild-type MC1R).  Alterations in horses with STX17 duplication 
(gray boxes/arrows): Horses with the duplication have additional binding sites for both MITF and NR4A3 (h), 
which are components of the normal MC1R signaling pathway. It is hypothesized that binding to these additional 
regulatory elements results in increased expression of NR4A3 and STX17 (i), which leads to altered regulation of the 
cell cycle and carcinogenesis (j). Increased binding of MITF also results in excessive melanocyte proliferation (k) 
which leads to exhaustion of hair follicle melanocytes and gray coat color (l) and abnormal proliferation (k) and/or 
regulation of apoptosis in dermal/epidermal melanocytes and melanoma (m). Altered MC1R signaling in horses 
with the ASIP deletion (blue boxes and arrows): In horses with the ASIP deletion, the antagonistic effect of ASIP is 
lost, resulting in a relative increase in MC1R signaling and increased cAMP levels compared to wild-type (n). 
Horses homozygous for this mutation (ASIPa/a) produce more eumelanin, resulting in black coat color (o). In horses 
with the STX17 duplication and the ASIP deletion, the relative increase in MC1R signaling from the ASIP deletion, 
results in higher levels of MITF and NR4A3, which exacerbates the abnormal cellular regulation with the gray 
genotype (h, i, j, k, l, m). In horses with the MC1R mutation (red boxes/arrows): MC1R signaling is altered and 
cellular cAMP levels are decreased (p). This alters pigment production causing a shift from eumelanin production to 
pheomelanin production (q). Pheomelanin is a red/orange pigment leading to the chestnut coat color in MC1R e/e 
horses (r). The impact of decreased MC1R signaling and thus decreased MITF and NR4A3 expression on 
melanoma susceptibility and severity in gray horses is unknown. 
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Figure 2. Vitiligo and speckling.  
2a) Loss of skin pigmentation around the anus of a non-gray horse (vitiligo). 2b) Gray 
horse with red pigmented spots (speckling).  
 
Rationale 
 
There are no diagnostic tests available to predict tumor behavior and metastasis risk in 
gray horse melanoma. By better understanding the genetic risk factors involved in melanoma 
susceptibility, young gray horses can be tested and classified into risk categories (i.e. low and 
high risk for melanoma development and low or high risk of metastasis) which may allow 
early intervention in horses that are more likely to develop severe, life threatening 
consequences to dermal melanomas; when therapy options are limited to nonexistent.   
 
Hypothesis for experiment 1 
 
 Up to 80% of gray horses older than 15 years develop melanomas 1,13, however, 
  
Figure 2a  Figure 2b  
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preliminary results from a large family of 20 gray QH, varying in age from 4 to 22 years 
old (mean age of 11.3 years) indicated that melanoma prevalence was low in this breed . 
We hypothesized that melanoma susceptibility and severity is lower in the gray QH 
population, compared to gray horses from other breeds. 
 
Aims for experiment 1 
 
 Determine the melanoma prevalence and grade in gray QHs and compare this 
prevalence and severity in gray horses of other breeds where melanoma prevalence 
and/or grade have been described.  
 
Hypothesis for experiment 2 
 
 An increase in MC1R signaling has been linked to increased melanoma prevalence 
and grade in gray horses. We hypothesized that melanoma susceptibility in gray QHs is 
lower than gray horses from other breeds due to decreased MC1R signaling resulting 
from a high incidence of the MC1R chestnut coat color allele in the QH population. 
 
Aims for experiment 2 
 
 Genotype over 300 gray QHs, with and without melanomas, for the STX17, ASIP 
and MC1R loci and determine the effect of decreased MC1R signaling on melanoma 
grade and severity, after accounting for the effect of age and the other two genotypes on 
12 
 
 
melanoma formation.  
 
Power calculation: Prior to the study, a random population of 48 Quarter Horses were 
genotyped for the chestnut and black alleles. In this population the frequency of the 
chestnut MC1Rc allele is 0.78 and the wild-type MC1RC allele is 0.22, thus the estimated 
genotypic frequencies for the chestnut genotypes from Hardy-Wienberg equilibrium are 
0.05, 0.34 and 0.61 for MC1RC/C, MC1RC/c and MC1Rc/c, respectively [(MC1RC/C)2 + 
2(MC1RC/c) + (MC1Rc/c)2 =1]. The frequencies of the black allele and wild type alleles in 
this population are ASIPa 0.32 and ASIPA 0.68, thus the estimated genotypic frequencies 
for the black locus are 0.46, 0.44 and 0.1 for ASIPA/A, ASIPA/a and ASIPa/a, respectively. 
These estimated population frequencies were used in power calculations to determine the 
ability to measure a possible effect of genotypes at these loci on melanoma incidence and 
severity. Assumptions used for power calculation are listed in Table 1.  
 
 Power calculations were performed for the ability to detect an effect of the chestnut 
locus on melanoma incidence and grade with α=0.05 and β=0.8, given the likely 
frequencies of the ASIP and MC1R genotypes in the QH population. The assumptions 
presented in Table 1 about genotypic effect on melanoma grade for power calculations 
were made. Standard deviation estimation of 1.0 was used for the power calculations 
based on the average standard deviations from the regression analysis in 694 Lipizzaners 
by Pielberg et al 5 and the regression analysis of melanoma susceptibility in 296 
Lipizzaners by Seletenhammer et al 17.  A reduction in R2 of 0.3 was used in the 
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calculations to account for  the 28% of total variability in melanoma grade due to age and 
stud farm reported by Seletenhammer et al 17. Based on the above assumptions, power 
calculations demonstrate that a study cohort of 300 gray Quarter Horses is required to 
detect an effect of the chestnut allele on melanoma grade and susceptibility. Analyses 
done by Seletenhammer et al17, and Pielberg5 et al included horses 4 years or 6 years of 
age and older, respectively, and while our power calculations take into account the 
variability due to age and stud farm, we limited our analysis to horses 5 years of age and 
older to assure optimal power.  Our goal was to identify a minimum of 300 additional 
gray QH (all ages) for inclusion in the study population to allow for accurate calculation 
of the impact of age on melanoma incidence, and assure that at least 300 horses aged 5 or 
older are available for analysis of the impact of MC1R genotype of melanoma grade.  
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Table 1. Genotypic effect on melanoma grade 
 
risk factor mean (± SE) melanoma grade frequency 
STX17G/G 1.43 ± 0.04a 0.5b 
STX17G/g 0.67 ± 0.05 a 0.5b 
ASIPA/A 0.88 ± 0.06 a 0.46d 
ASIPA/a 1.06 ± 0.04 a 0.44d 
ASIPa/a 1.22 ± 0.07 a 0.1d 
MC1RC/C 1.18c 0.05d 
MC1RC/c 0.89c 0.34d 
MC1Rc/c 0.6c 0.61d 
a least squares mean of melanoma grade from polynomial regression analysis in a 
population of 694 gray Lipizzaner horses in Pielberg et al. 5 
b population frequencies of each gray genotype based on the data from Pielberg et al. 1 
c predicted effect of the MC1R locus genotypes estimated from the magnitude of effect of 
the ASIP genotypes in Pielberg et al. 5 
d estimated population frequencies of each genotype in Quarter Horses based on a 
population of 48 random Quarter Horses (preliminary data) 
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Chapter 2 
Experiment 1 
Melanoma Prevalence and Grade in Gray Quarter Horses 
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Introduction 
 
 Gray horses are born any color and turn gray with age. A strong correlation 
between the gray coat color and melanoma development has long been recognized with 
80% of gray horses older than 15 years of age developing melanomas 1,13. The genetic 
link between the gray coat color and melanoma development has recently been 
identified5. All dermal melanomas have the potential to metastasize and histopathology of 
the tumor cannot predict metastasis risk4.  
 While the majority of gray horses older than 15 years of age will develop 
melanomas1, 13, a large family of 20 gray horses ranging in age from 3 to 22 years old 
(mean age of 11.3 years) with no external melanoma was identified. Experiment 1 was 
designed to investigate if melanoma prevalence and grade is lower in gray QHs in general 
or if this lower susceptibility is present just in the family of gray horses identified.  
 The overall purpose of this study was to determine melanoma prevalence and grade 
in gray QH and compare it with gray horses from other breeds where those parameters 
have been described. Melanoma prevalence and grade have been studied in the 
Lipizzaner, Pura Raza Espanola and Camargue breeds.  
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Materials and Methods 
 
Study population and sample collection. Age, gender and melanoma phenotype data were 
collected from 335 gray QH. Phenotype data included the presence, location, size and 
appearance of external melanomas recorded using a standardized form, and digital 
photography of melanomas (if present). Horses were assigned a melanoma grade 0-4 (in 
½ grade increments) by a single investigator (RT) according to the scale of Peilberg et al5 
(Table 2).  
 
Table 2. Melanoma grading system (Rosengren et al, 2008)1 
 
Grade Description 
0 No melanoma 
1 Early stages of plaque-type or one solitary nodule of 0.5 cm or less 
2 
Several nodules of 0.5 cm or less or a single solitary nodule of 2 cm or 
more 
3 One or several nodular melanomas 5 cm or more 
4 Extensive confluent melanoma, necrosis or ulceration, or metastasis 
 
Statistical analysis. Statistical analyses were performed using R statistical software. 
Descriptive statistics were calculated for age, gender, melanoma prevalence and grade. 
Age was evaluated as a continuous and categorical variable (1-4 years, 5-9 years, 10-14 
years, 15-19 years and > 20 years or a dichotomous variable (≥15 years versus <15 
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years). Gender was coded as gelding, stallion or female and as male (stallion and gelding) 
and female. Univariate regression was used to test for the individual effect of age on 
melanoma case/control status (logistic regression) and melanoma grade (linear 
regression). Age was fit as a cubic term in the linear regression to better model the 
relationship between age and melanoma grade in the study cohort. Chi square test and 
regression models including age were performed to detect significant differences in 
melanoma prevalence between genders.  Multiple regression analysis was performed 
using age (cubic) and gender to further evaluate for an effect of gender on outcome.  
 
For all analyses, differences were accepted as significant when p ≤ 0.05.  
 
This protocol was approved by the University of Minnesota’s Institutional Animal Care 
and Use Committee. Owner consent was obtained prior to the enrollment of horses.  
 
Results 
 
Melanoma prevalence and grade 
 Three hundred and thirty-five gray QH, 227 females, 87 geldings and 20 stallions, 
and 1 of unknown gender were phenotyped for dermal melanoma. Age ranged from 1 to 
33 years (mean 9.21). Age was not recorded in four horses. Fifty-six horses (16.72%) had 
visible dermal melanomas and were classified as cases.  Of these 56 cases, 28 (50%) had 
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a solitary mass, and 28 (50%) had two or more masses (mean number of masses per horse 
3.2; range 2-8). Melanomas were most commonly under the tail (74.5%), followed by 
around the anus (18%), at the commissure of the lip (10.9%), surrounding the parotid 
salivary gland (9%), on the prepuce (9%) or external genitalia (7.2%) and on the neck 
(7.2%). Less common locations included: base of the ear, submandibular region, udder, 
medial aspect of the hind legs, forehead, shoulder, flank, and gluteal, abdominal or 
thoracic regions. In horses that had masses in 2 or more locations; 89.28% had masses 
under the tail and in a second location; only 10.71% of horses with masses in multiple 
locations did not have melanomas under the tail. Melanoma grade distribution in the case 
cohort is presented in Table 3. Mean melanoma grade across the case cohort was 2.15, 
with only 7% of the horses assigned a grade 4 with ulcerated masses (Figure 3).  In no 
cases were the masses interfering with normal vital functions (defecation/urination). 
None of these horses had a history of weight loss or other complaints associated with 
melanoma. No significant difference in melanoma prevalence or mean melanoma grade 
was observed across genders (Table 4).   
 Melanoma cases ranged in age from 2 to 30 years, with clear increase in melanoma 
prevalence with age (Table 5); prevalence was 51.92% in horses >15 years compared to 
10% in horses <15 years. Age was significantly associated with the presence or absence 
of melanoma (logistic regression p=5.28x10-11). Similarly, melanoma grade increased 
with age, mean melanoma grade was lowest in cases between 1 and 4 years (1.63) and 
highest in cases ≥ 20 years (2.68) (Table 5). Age was also significantly correlated with 
melanoma grade (linear [cubic] regression: Spearman’s correlation coefficient= 0.387, 
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p=2.2x10-13).   
 
GRADE 1 GRADE 2 GRADE 3 GRADE 4  
Figure 3. Example of melanoma grades 1-4.  
a. Grade 1 melanoma around the anus: one solitary nodule of 0.5 cm or less. b. Grade 2 
melanoma under the tail: several nodules of 0.5 cm or less. c. Grade 3 melanoma in the 
parotid gland region: one nodular melanoma 5 cm or more. d. Grade 4 melanoma under 
the tail: extensive confluent melanoma with the presence of necrosis, ulceration or 
metastasis.  
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Table 3. Distribution of melanoma grades in the case cohort 
 
Melanoma 
grade 
Count (%) 
1 13 (21.82%) 
1.5 9 (16.36%) 
2 8 (14.55%) 
2.5 12 (21.82%) 
3 9 (16.36%) 
3.5 1 (1.82%) 
4 4 (7.27%) 
Total 56 
 
 
 
 
 
 
Table 4. Breakdown of melanoma prevalence and mean melanoma grade by gender 
 
Gender 
Total 
number 
of horses 
Number 
of 
melanoma 
cases 
Melanoma 
prevalence 
(%) 
Mean melanoma 
grade (mean ± sd) 
entire cohort* 
Mean melanoma 
grade (mean ± 
sd) cases only** 
Female 227 35 15.42 0.36 ± 0.92 2.36 ± 0.85 
Gelding 87 17 19.54 0.34 ± 0.80 1.76 ± 0.87 
Stallion 20 4 20.00 0.40 ± 0.90 2.00 ± 0.91 
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Table 5. Breakdown of melanoma prevalence and mean melanoma grade by age 
 
Age 
Total 
number 
of 
horses 
Number of 
melanoma 
cases 
Melanoma 
prevalence 
(%) 
Melanoma 
grade 
(mean ± 
sd) entire 
cohorta 
Mean 
melanoma 
gradeb 
1-4 79 4 5.06 
0.082 
±0.38 
1.63 
5-9 107 8 7.48 
0.126 
±0.48 
1.69 
10-14 94 16 17.02 
0.372 
±0.90 
2.19 
15-19 26 13 50.00 
1.000 
±1.14 
2.07 
≥20 25 14 56.00 
1.500 
±1.52 
2.68 
Totalc 335 56 16.72 
0.359 
±0.88 
2.15 
<15 280 28 10.00 
0.196 
±0.64 
1.96 
≥15 51 27 51.92 
1.245 
±1.35 
2.35 
 
            aMean melanoma grade calculated across the entire cohort 
               bMean melanoma grade calculated only when melanoma was present (ie within the melanoma cases) 
 cThe total number of horses is not equivalent to the summation of the horses in the different age 
categories because age is unknown in 4 animals (3 controls and 1 case)  
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Discussion 
 
 To date, studies of melanoma grade and prevalence have been limited to the 
Lipizzaner, Pura Raza Española (Spanish pure breed or Andalusians of Spanish origin) 
and Camargue breeds13, 17,18.  
 The melanoma prevalence in our QH cohort was 16.72%, which is lower than 
previously described in the Lipizzaner (50%), Camargue (31.4%) and Pura Raza 
Española (89.6%). Our study confirmed the effect of age on melanoma prevalence in 
gray QH horses as previously described1, 13,3. However, the melanoma prevalence in QH 
older than 15 years old (51.92%) in our study was still much lower than the prevalence 
reported in Lipizzaner (75%) and Camargue (68%) horses older than 15 years3, 13, or Pura 
Raza Española horses and crosses older than 10 years (100%)18. Further, the mean 
melanoma grade in this entire cohort was 0.35 (scale 0 to 4), and 2.15 in cases alone 
(horses with melanoma), which is again lower than melanoma grade reported in a 
population of 296 gray Lipizzaner horses, where mean melanoma grade across the entire 
study population was 1.19 and 2.40 in cases (grades 0-4) 17.  The same grading system 
was used between studies, so inter-investigator variability is unlikely based on the 
qualitative nature of the grading scale and the marked difference between grades.   
 The most common locations for melanoma development observed in the present 
study are consistent with previous reports. Also, no effect of gender was observed on 
melanoma prevalence and/or grade in the present study or previous studies.   
 In conclusion, melanoma prevalence and grade appears to be lower in gray QHs, 
compared with gray horses from other breeds.  
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Chapter 3 
Experiment 2 
Genetic Susceptibility of Melanoma in Gray Quarter Horses 
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Introduction 
 
 Graying and melanoma in horses have been linked to a 4.6 kilobase duplication in 
intron 6 of the syntaxin-17 (STX17) gene5. This duplication harbors a regulatory element 
containing binding sites for microphthalmia-associated transcription factor (MITF) and 
NR4A3, key components in the regulation of melanocyte gene expression and cell 
function6.  The expression of both STX17 and its neighboring gene, NR4A3, are up-
regulated in gray horse melanomas, suggesting that the duplicated region is a 
melanocyte-specific, cis-acting regulatory element. MITF and NR4A3 mediated up-
regulation of melanin production and proliferation of hair follicle and dermal/epidermal 
melanocytes is the hypothesized link between the STX17 mutation, gray coat color and 
melanoma formation5. Horses that are homozygous for the STX17 duplication have two 
additional copies of the regulatory element and have a higher melanoma incidence and 
higher mean melanoma grade than heterozygous gray horses, which have only a single 
extra copy of the regulatory element6.  NR4A3 and MITF transcription are mediated by 
signaling through the melanocortin-1-receptor (MC1R) pathway that results in increase in 
cellular cAMP concentration (Figure 1). MC1R signaling is antagonized by the agouti-
signaling protein (ASIP) resulting in decreased cAMP, MITF and NR4A3 expression 
(Figure 1). Horses carrying a deletion in exon 2 of the ASIP gene that results in a loss of 
ASIP antagonistic function7 have increased signaling through the MC1R pathway and 
homozygotes are black in color. The relative increase in MC1R signaling in horses with 
the ASIP mutation has been linked to increased melanoma severity5.   
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 The purpose of the present study was to determine the effect of decreased MC1R 
signaling associated with the MC1R chestnut allele on melanoma grade and severity in 
gray QHs. The final goal was to better understand the genetic basis of melanoma 
susceptibility in gray horses and develop a screening PCR test to be used in young gray 
horses, prior to melanoma formation, which would allow identification of animals at a 
greater risk of developing severe consequences of dermal melanomas. This would allow 
veterinarians and horse owners to make informed decisions prior to embarking on 
expensive therapy and would also allow selection of cases that are candidates for early 
intervention, prior to the development of metastasis.  
  
Material and Methods 
 
Study population and sample collection. Age, gender, melanoma phenotype and samples 
for isolation of genomic DNA (whole blood [EDTA] or hair root samples) were collected 
from 335 gray QH. Phenotypic data included the presence, location, size and appearance 
of external melanomas recorded using a standardized form, and digital photography of 
melanomas (if present). Horses were assigned a melanoma grade 0-4 (in ½ grade 
increments) by a single investigator (RT) according to the scale of Peilberg et al5 (Table 
2).  
 
Sample recruitment and phenotyping. Samples were collected and phenotyped as 
described in Chapter 2.  
27 
 
 
 
DNA isolation. Genomic DNA was isolated from whole blood or hair roots with 
commercially available kits according to the manufacturers’ protocols (Purogene Blood 
Kit C for whole blood and Qiagen's DNeasy Blood and Tissue Kit following the 
procedure for animal tissues for hair root isolations).  
 
Genotyping.  Horses were genotyped for gray (STX17), chestnut (MC1R) and agouti 
(ASIP) locus. Genotyping for gray was performed using the long range PCR method 
described by Peilberg et al.5 and was recorded as heterozygous (STX17G/g) or 
homozygous (STX17G/G) gray. Chestnut was genotyped using the restriction fragment 
length polymorphism assay described by Marklund et al8; genotypes were recorded as 
homozygous wild-type MC1RE/E, heterozygous MC1RE/e, or homozygous MC1Re/e 
chestnut. Genotyping agouti was performed using PCR amplification and detection of the 
ASIP deletion by resolution of PCR products on a 4% agarose gel as described by Rieder 
et al7. Agouti genotypes were recorded as homozygous wild-type ASIPA/A (bay), 
heterozygous ASIPA/a (bay), or homozygous ASIPa/a (black). 
 
Statistical analysis. Statistical analyses were performed using R statistical software. 
Genotypes were coded as additive (0, 1 or 2 copies of the risk allele), recessive effect 
(aa=1 and Aa or AA=0), where a and A are the risk alleles and wild-type respectively, 
dominant (aa or Aa=1 and AA=0), or genotypic (aa, Aa, and AA represent three factor 
levels for genotype) (Table 6).  Additive, recessive and dominant coding is relative to the 
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derived (mutant) allele. Both dominant and recessive coding has two levels of effect: 0 or 
1. Additive coding allows each additional copy of the risk allele to result in a simple 
additive increase in risk, with three different levels of effect: 0, 1 or 2. Genotypic coding 
also allows for three different levels of effect (one for each genotype), however the effect 
differences do not have to be additive; in this circumstance the genotype coding is 
categorical. For example, genotypes AA, Aa, and aa, could have effects of 0, 2 and 6 
respectively, or in a scenario where heterozygotes had the highest risk effects for AA, Aa, 
and aa could be 0, 6 and 2 respectively. The genotypic model treats all three genotypes as 
independent categories, without assigning an a priori guess as to the effect (ie does not 
have to be additive, dominant or recessive).  
 
Table 6. Allele coding for each genetic model considered in regression analyses.  
 
 Genotype coding for regression analyses 
Genotype Additive Recessive Dominant Genotypic 
MC1R E/E 0 0 0 E/E 
MC1RE/e 1 0 1 E/e 
MC1R e/e 2 1 1 e/e 
ASIP A/A 0 0 0 A/A 
ASIP A/a 1 0 1 A/a 
ASIP a/a 2 1 1 a/a 
STX17 G/g 1 0 1 G/g 
STX17 G/G 2 1 1 G/G 
 
 All horses in the study cohort were gray; therefore, the homozygous wild type 
genotype STX17g/g was not present in this data. 
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 Chi-square tests were performed to identify significant deviation of genotypes from 
Hardy-Weinberg expectations. Multiple regression was performed using age (cubic), 
STX17, MC1R and ASIP on melanoma grade (linear regression), or case/control status 
(logistic regression) as the phenotypic response. Multiple regression models also included 
terms to model interaction between age and genotype and interactions between MC1R 
and ASIP genotype (see Equations and Figure 3 for details of multiple modeling). 
Multiple regressions were performed in the entire cohort and repeated after limiting the 
analysis to horses > 5 years, or to melanoma cases.  
 Since we hypothesize that the high frequency of the MC1R chestnut allele (MC1Re), 
and subsequent decrease in MC1R signaling, results in decreased melanoma prevalence 
and/or melanoma severity, we explored several multiple regression models to test this 
global hypothesis:   
 Equations: 
1. melanoma= µ + age (cubic) + genotype + random error (є) 
2. melanoma= µ + age (cubic) + genotype + genotype*age + random error (є) 
3. melanoma= µ + age (cubic) + STX17 genotype+ MC1R genotype+ ASIP genotype 
+  random error (є) 
4. melanoma= µ + age (cubic) + MC1R genotype + ASIP genotype + random error 
(є) 
5. melanoma= µ + age (cubic) + MC1R genotype + ASIP genotype + MC1R 
genotype*ASIP genotype + random error (є) 
6. melanoma= µ + age (cubic) + STX17 genotype+ MC1R genotype+ ASIP genotype 
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+ STX17 genotype*age + MC1R genotype*age + ASIP genotype*age + random 
error (є) 
 
 For all models, melanoma is either melanoma grade (linear regression), or 
case/control status (logistic regression), age is modeled as a cubic variable, genotype is 
coded as either additive, recessive, dominant or genotypic (Table 6), genotype*age 
indicates an interaction term between age and genotype, and MC1R genotype* ASIP 
genotype indicates an interaction term between the genotypes at both loci. 
 Equations 1 and 2 address the most straightforward questions, i.e., does the 
genotype at this locus affect melanoma (prevalence or grade) after accounting for the 
effect of age (1), and does the relationship between genotype and melanoma vary with 
age (2). Equation 3 is a multivariate regression equation simultaneously considering the 
effects of all 3 genotyped loci.  
 Equations 4 and 5 explore the relationship between MC1R and ASIP:  Equation 4 
tests for an effect of MC1R after accounting for ASIP (Figure 1); this hypothesis was also 
evaluated by testing for the effect of MC1R in only ASIPAA homozygotes. Equation 5 
tests for interaction between the two loci, i.e., does the effect of either genotype depend 
on the genotype at the other locus. For this test, genotypes at MC1R were coded as 
recessive to test the hypothesis that in the absence of normal MC1R signaling (i.e., 
MC1Ree), the effect of the ASIP mutation would be null (Figure 4b), and MC1R 
genotypes were coded as additive to test the hypothesis that the effect of the ASIP 
mutation is mitigated by the MC1Re allele (Figure 4c).  
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 Equation 6 represents the full model of the data. These analyses were explored both 
across the entire cohort and within cases only.  
 
For all analyses, differences were accepted as significant when p ≤ 0.05.  
 
This protocol was approved by the University of Minnesota’s Institutional Animal Care 
and Use Committee. Owner consent was obtained prior to the enrollment of horses.  
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Figure 4. Previously reported effect of the ASIP mutation on melanoma grade (a)5, 
and 2 hypotheses tested for the effect of MC1R on melanoma risk and grade in gray 
horses (STX17GG or STX17Gg) (b, c).  
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The horses initial coat color (prior to graying) based on ASIP and MC1R genotypes is 
indicated inside boxes. a) Effect of the ASIP mutation on increasing melanoma grade 
with increased copies of the mutated “a” allele as reported by Rosengren et al5. b) 
Hypothesis 1: Homozygosity for the chestnut allele (MC1Ree) nulls the effect of the ASIP 
“a” allele; i.e. there is not an ASIP effect on MC1Ree horses. Statistically, this hypothesis 
was tested by coding the MC1R genotype as recessive and the ASIP genotype as additive, 
and testing for the interaction between the loci. c) Hypothesis 2: The MC1R mutation 
decreases melanoma risk and/or grade depending on the number of copies of the mutated 
allele “e”, and the ASIP mutation increases melanoma risk with increased copies of the 
mutated allele “a”. In this scenario, for statistical analysis, both genotypes were coded as 
an additive effect and the interaction between the MC1R and ASIP loci was tested.  
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Figure 5. Testing for the effect of MC1R genotype.   
The horses initial coat color (prior to graying) based on ASIP and MC1R genotypes is 
indicated inside boxes. The darker the box, the greater is the melanoma risk/grade. a) 
Recessive effect of MC1R, independent of ASIP. b) Dominant effect of MC1R, 
independent of ASIP. c) Additive effect of MC1R, independent of ASIP.  
	  
Results 
 
Genotypes (MC1R, ASIP, STX17) 
 326 horses were successfully genotyped for ASIP, 320 horses for MC1R and 311 
horses for STX17. In this cohort, the wild-type allele, ASIPA, was the major allele at the 
agouti locus (allele frequencies ASIPa 0.32, ASIPA 0.67), and the mutant alleles were the 
major alleles at the MC1R and STX17 loci (allele frequencies: MC1Re 0.76, MC1RE 0.23; 
STX17G 0.53, STX17g 0.46). Genotype frequencies for ASIP and MC1R were consistent 
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with Hardy-Weinberg expectations (p =0.294 and p =0.244, chi-square test for derivation 
from Hardy-Weinberg equilibrium) (Table 7). Due to the sampling scheme that collected 
only gray horses, Hardy-Weinberg expectations could not be tested for STX17 genotype 
frequencies; however STX17G/G homozygotes (7.07%) were much less frequent than 
STX17G/g heterozygotes (92.93%)  (Table 7).  
 
Table 7.Genotype and allele frequencies for ASIP, MC1R and STX17 and mean 
melanoma grade for each genotype. 
 
Genotype 
Total 
numbe
r of 
horses 
Number 
of 
melanoma 
cases 
Genotype 
frequenc
y (%) 
Melanom
a 
prevalenc
e (%) 
Melanoma 
grade (mean 
± sd) entire 
cohort a 
Melanoma 
grade 
(mean ± sd) 
Cases only b 
ASIPA/A 145 23 44.47 15.86 0.317 ±0.82 2.000 ±0.94 
ASIPA/a 151 28 46.31 18.54 0.407 ±0.92 2.196 ±0.83 
ASIPa/a 30 3 9.20 10.00 0.283 ±0.86 2.833 ±0.28 
MC1RE/E 16 2 5.00 12.50 0.156 ±0.43 1.250 ±0.35 
MC1RE/e 118 22 36.87 18.64 0.419 ±0.95 2.250 ±0.89 
MC1Re/e 186 29 58.12 15.59 0.327 ±0.83 2.103 ±0.85 
STX17G/g 289 46 92.92 15.91 0.346 ±0.87 2.173 ±0.89 
STX17G/G 22 6 7.07 27.27 0.522 ±0.96 1.916 ±0.86 
 
aMean melanoma grade calculated across the entire cohort 
bMean melanoma grade calculated only when melanoma was present (ie within the melanoma cases) 
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Effect of genotype on melanoma prevalence 
 Melanoma prevalence by genotype at each locus is presented in Table 7. 
Melanoma prevalence was almost two times greater in STX17G/G homozygotes when 
compared to STX17G/g heterozygotes (27.27% versus 15.91%). Melanoma prevalence did 
not appear to follow a particular pattern in MC1R (MC1RE/E 12.5%, MC1RE/e 18.64%, 
and MC1Re/e 15.59%) or ASIP (ASIPA/A 15.86%, ASIPA/a 18.54%, and ASIPa/a 10.0%) 
genotypes.  Due to the large effect of age on melanoma prevalence, logistic regression 
with age as covariate was used to determine the effect of genotype on melanoma 
prevalence. Even after accounting for age in this manner, no significant differences in 
melanoma prevalence due to genotype were identified for STX17, MC1R or ASIP in any 
of the genetic models considered (i.e. additive, dominant, recessive or genotypic). 
Further, no significant differences in melanoma prevalence were detected when ASIP, 
MC1R or STX17 were considered together in a multiple regression, or when age by 
genotype interactions were included in the models.   
 
Effect of genotype on melanoma grade 
 The mean melanoma grade (grades 1-4) for each genotype across the entire cohort 
is presented in Table 7. The mean melanoma grade was higher in STX17G/G homozygotes 
when compared to STX17G/g heterozygotes (Table 7). When mean melanoma grade was 
calculated using only the case cohort however, STX17G/G homozygotes had a lower mean 
melanoma grade than STX17G/g heterozygotes.  Further, melanoma grade calculated in 
only the case cohort followed a pattern consistent with an additive effect of the ASIPa 
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allele on melanoma grade.  Linear regressions with age as a covariate were fit to test for 
an effect of genotype on melanoma grade after accounting for age. Due to the dramatic 
effect of age on melanoma grade, the estimated effect of each genotype after accounting 
for age (least squares mean) and the estimated effect of genotype at 20 years of age are 
shown in Tables 8 and 9. After accounting for age, no statistically significant effects of 
genotype were identified. To test for varying effects of genotype with age, age by 
interaction terms were included in the model (see Equations), no age by genotype 
interactions were detected.  
 
Table 8.Least squares means and fit at age 20 across the entire cohort of samples. 
 
 
genotype + age3 genotype + age3 + interaction 
Genotype 
least squares 
means (±SE)a 
fit at 20 years 
of age (±SE) 
least squares 
means (±SE) a 
fit at 20 years 
of age (±SE) 
ASIPA/A 0.15 (±0.08) 1.18 (±0.13) 0.15 (±0.08) 1.09 (±0.15) 
ASIPA/a 0.26 (±0.07) 1.29 (±0.12) 0.26 (±0.07) 1.31 (±0.14) 
ASIPa/a 0.21 (±0.15) 1.23 (±0.18) 0.25 (±0.15) 1.59 (±0.35) 
MC1RE/E 0.11 (±0.20) 1.11 (±0.23) 0.08 (±0.20) 0.50 (±0.59) 
MC1RE/e 0.26 (±0.08) 1.25 (±0.13) 0.26 (±0.08) 1.42 (±0.16) 
MC1Re/e 0.20 (±0.07) 1.19 (±0.12) 0.21 (±0.07) 1.08 (±0.14) 
STX17G/g 0.21 (±0.06) 1.20 (±0.12) 0.20 (±0.06) 1.22 (±0.13) 
STX17G/G 0.40 (±0.17) 1.40 (±0.20) 0.40 (±0.17) 1.32 (±0.40) 
aMean age for ASIP= 9.21, mean age MC1R= 9.21, mean age STX17= 9.24 
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Table 9.Least squares means and fit at age 20 within the case cohort.  
 
 
genotype + age3 genotype + age3 +interaction 
Genotype 
least squares 
means (±SE)a 
fit 20 years of 
age (±SE) 
least squares 
means (±SE) a 
fit  20 years of 
age (±SE) 
ASIPA/A 1.89 (±0.22) 2.11 (±0.26) 1.92 (±0.23) 2.24 (±0.30) 
ASIPA/a 2.17 (±0.18) 2.39 (±0.22) 2.18 (±0.19) 2.35 (±0.24) 
ASIPa/a 2.76 (±0.49) 2.98 (±0.50) 2.79 (±0.51) 2.94 (±0.62) 
MC1RE/E 1.40 (±0.66) 1.62 (±0.69) 1.84 (±1.27) 2.38 (±1.95) 
MC1RE/e 2.16 (±0.20) 2.38 (±0.23) 2.16 (±0.21) 2.38 (±0.24) 
MC1Re/e 2.08 (±0.21) 2.30 (±0.26) 2.06 (±0.21) 2.31 (±0.29) 
STX17G/g 2.13 (±0.17) 2.37 (±0.22) 2.18 (±0.17) 2.43 (±0.22) 
STX17G/G 1.95 (±0.37) 2.19 (±0.39) 1.81 (±0.38) 1.66 (±0.54) 
aMean age for ASIP= 15.49, mean age MC1R= 15.27, mean age STX17= 15.48 
 
Interactions between MC1R and ASIP 
 The hypothesized effects of ASIP, MC1R and STX17 are all mediated through the 
MC1R signaling pathway, thus genotype by genotype interaction terms were modeled. In 
particular, the potential interaction between ASIP and MC1R were explored as the 
MC1Ree genotype is epistatic over ASIP in relation to coat color (Figure 1, Figures 4 
and 5). Across the entire sample cohort, no significant effects of either ASIP or MC1R 
were detected after accounting for genotype at the other locus (equation 4). Further, no 
interaction was detected between the two loci when the effect of MC1R was coded as 
additive or recessive (equation 4). When the effect of ASIP and MC1R on grade was 
considered in melanoma cases, there was a suggested additive effect of ASIP (p=0.077).    
 Similar results in all analyses were obtained when the cohort was restricted to 
horses greater than 5 years of age (data not shown).  
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Discussion 
 
 Studies of melanoma grade and prevalence have been limited to the Lipizzaner, 
Pura Raza Española (Spanish pure breed or Andalusians of Spanish origin) and 
Camargue breeds13,17,18. In these breeds gray coat color is predominant or breed-defining, 
the ASIP mutation is relatively common, and the MC1R chestnut allele is absent or 
segregating at extremely low frequency5. Thus the potential impact of altered MC1R 
signaling associated with the MC1R chestnut mutation on melanoma development and 
grade cannot be evaluated in any of these three breeds.  The high chestnut allele 
frequency and resulting high homozygous chestnut genotype frequency in our gray QH 
cohort made it possible to determine the effect of diminished MC1R signaling resulting 
from this mutation on melanoma risk. 
 In a population of 694 Lipizzaner horses, the number of STX17 duplications 
appeared to impact melanoma risk, as STX17 homozygotes had greater melanoma 
prevalence than STX17 heterozygotes, and the estimated mean melanoma grade (least-
squares mean) for heterozygotes was 0.67 compared to 1.43 for homozygotes5. In our 
study cohort, melanoma prevalence and mean melanoma grade were higher in horses 
homozygous for the gray mutation (27.27% and 0.52, respectively), compared to 
heterozygous gray horses (15.91% and 0.34, respectively), although this difference was 
not statistically significant. There were very few homozygous gray horses in the study 
cohort (n=22) and only 6 of these horses had melanoma, resulting in poor statistical 
power to demonstrate the effect of the additional copies of the STX17 mutation on 
melanoma prevalence and/or grade. The low frequency of the SXT17 homozygosity in 
39 
 
 
our population is not surprising, as QH are not primarily bred for the gray coat color.   
 Work in the Lipizzaner breed also demonstrated an effect of the ASIP genotype on 
melanoma grade after accounting for the gray genotype. The effect of the ASIP deletion 
in that study was estimated as 1.06 (least-squares mean) for heterozygotes (ASIPA/a) and 
1.22 for homozygotes (ASIPa/a) 5. We did not detect a statistically significant effect of the 
ASIP mutation on melanoma grade in our study cohort. There are several possible 
explanations for this result. First, although no effect of the ASIP deletion was observed, a 
trend of increasing mean melanoma grade with increased copy of the mutate allele 
(ASIPa) was observed in melanoma cases (Table 7); however after accounting for age 
(Table 8), these differences were not statistically significant. The confidence intervals 
around the estimated additive effect of the ASIP deletion on melanoma grade in our study 
cohort (estimate: 0.07; 95% CI -0.065 to 0.204) overlap with the additive effect reported 
by Pielberg et al (0.16-0.18)5.  
 It is also possible that the presence of the MC1R mutation mitigates an effect of the 
ASIP mutation on melanoma grade. Although we did not find a significant effect of the 
MC1R mutation itself, it is conceivable that the altered signaling in MC1R heterozygotes 
and homozygotes, specifically decreased levels of cAMP, balance the up-regulation of 
signaling in horses with the ASIP mutation (Figure 1).   A high frequency of the MC1R 
mutation and the MC1Re/e and MC1RE/e genotypes were observed in this cohort. Only 5% 
of the horses were homozygous wild-type for the chestnut MC1R gene (MC1RE/E), thus 
the vast majority of horses in this study had decreased MC1R signaling relative to wild-
type.  Although, we did not identify a statistically significant interaction between these 
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two genotypes, the low frequency of the MC1RE/E genotype resulted in poor statistical 
power for identification of this interaction. It is possible that the ASIP mutation has little 
to no effect on melanoma grade in the presence of the MC1R mutation due to decreased 
signaling through that pathway.  
 Another possible explanation for the lack of association between the ASIP mutation 
and melanoma grade is that the ASIP mutation might not be the functional allele 
underlying increased melanoma risk in Lipizzaners. In humans, ASIP variants have been 
shown to directly alter pigmentation phenotypes; and large genome wide association 
studies have implicated haplotypes containing ASIP in melanoma risk19,20. Yet, 
associations between specific variants in the ASIP gene and melanoma have not been 
demonstrated21,22, leading to speculation that in humans, the increase risk for melanoma 
is attributed to other genes within the associated haplotype19,20. Thus, it is possible that 
the genetic variant responsible for increased risk in Lipizzaner horses is simply in linkage 
disequilibrium with the ASIP mutation, and is not the ASIP mutation itself. Due to 
differences in haplotype length between those two breeds, the two alleles might not be in 
linkage disequilibrium in QH, preventing detection of a positive association.  
 Although genetic variants in MC1R pathway and/or MITF regulated genes 
frequently underlie melanoma risk in humans, the pathophysiology of melanoma appears 
to be very distinct from horses. An increase in MC1R signaling associated with increased 
melanoma risk in horses5 is in contrast with decreased MC1R signaling that is associated 
with red hair, fair skin, freckles, poor UVR-induced tanning response and increased 
melanoma risk in people23. Gray horses maintain dark pigmentation in the skin through 
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the process of graying and commonly develop melanomas in areas that are not exposed to 
the sunlight, thus UV exposure is unlikely an important environmental component in gray 
horse melanoma. Although MC1R variants are associated with increased melanoma risk 
in people, it was recently demonstrated that melanoma patients carrying MC1R variants 
had a better outcome than melanoma cases with black/brown hair, suggesting that MC1R 
mutations have a protective effect on survival. Signaling through MC1R regulates 
expression of the MITF transcription factor (Figure 1) that has many target genes in 
addition to pigment biosynthesis enzymes, including genes that regulate DNA repair, the 
cell cycle, apoptosis and invasion. The hypothesis is that melanoma cells carrying MC1R 
variants have less resistance to apoptosis, less sustained proliferation and poorer DNA 
repair, leading to better patient survival10. Although we found no effect of the MC1R 
mutation on melanoma prevalence/grade in gray QH, it is possible that this genotype is 
also associated with better survival in horses.  
 
 
 
 
 
 
 
42 
 
 
Chapter 4 
Conclusions and Future Directions 
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Conclusions 
 
 All dermal melanomas should be considered potentially malignant since 
histopathologic changes and location cannot predict the risk of metastasis4. Therapy for 
equine melanoma is most effective prior to extensive invasion of local tissue or 
metastasis. When surgical removal is not feasible due to the size or location of masses, 
intralesional injection of cisplatin11 or cisplatin beads12 may be palliative for masses 
interfering with essential functions such as urination and defecation13,3,11,14. When 
metastasis has occurred, systemic cimetidine or autologous vaccine are the only 
therapeutic options4,15, however both have relatively low efficacy unless initiated prior to 
the development of complications15. A better understanding of the risk factors involved in 
melanoma susceptibility, severity, and the risk of metastasis may allow for better 
prediction of tumor behavior and allow early intervention in horses that are more likely to 
develop severe, life threatening consequences to dermal melanomas. Classification of 
melanoma patients into risk categories (high and low risk groups) based on genetic 
predispositions would allow veterinarians to identify patients that are candidates for early 
intervention, before therapy options are limited, enabling owners and veterinarians to 
make informed decisions prior to embarking in expensive or prolonged treatment 
regimens. In humans, genetic testing is routinely used to identify individuals at high-risk 
for melanoma formation16.  
 
 Our findings suggest a lower prevalence and severity of melanoma in gray QH 
compared to other breeds in which melanoma prevalence and grade have been 
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investigated, but could not conclusively tie this decrease in prevalence and severity to 
altered MC1R signaling. Further work is needed to determine if the decreased prevalence 
and severity of melanoma in gray QH is simply due to infrequent STX17 homozygosity, a 
potential mitigating effect of the MC1R mutation on ASIP mediated enhancement of 
melanoma progression, or other genes in the MC1R pathway. Addressing these 
possibilities would require an expanded cohort of melanoma cases and controls and/or 
investigation of other loci.  It is also possible, as in humans, that carrying MC1R variants 
do not prevent horses from getting melanomas, but rather provide better survival rates. A 
prolonged follow up of this cohort would be necessary to prove this hypothesis.   
 
Future Directions 
 
 The low melanoma prevalence and grade observed in gray QH reinforces the need 
for future research in the area. While increasing the sample size would improve our 
power to detect an effect of the studied genotypes on melanoma prevalence/grade, 
inclusion of hundreds of gray QH is this study might not be feasible. Since gray horse 
melanoma is a complex genetic disorder, other approaches (apart from candidate gene 
studies) would make it possible to identify additional loci involved on melanoma 
susceptibility. Genome wide association studies and next generation sequencing 
technology are possible approaches to answer those questions.  
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I. Genome wide association studies - GWAS 
 Melanoma development in horses appears to be a complex disease, where multiple 
genes with different effects are responsible for the phenotype. While the STX17 mutation 
appears to be a gene of major effect, other genes are involved in the pathway5. To further 
elucidate genomic regions involved in melanoma susceptibility in gray QHs, genome 
wide association analysis (GWAS) could be performed. GWAS aims to identify 
associations between SNPs (single nucleotide polymorphism) and a trait. GWAS is less 
hypothesis driven and involves characterization of a much larger number of SNPs. The 
goal is to identify regions of the genome, highly associated with the phenotype in 
question (SNPs that vary systematically between cases and controls) 31, 32, 33. Those 
regions are further evaluated to identify possible candidate genes for further genotyping 
and validation in cases and controls. GWAS analysis relies on the concept of linkage 
disequilibrium (LD), which is the non-random association between markers and the 
causal allele. There is a low chance of recombination between two loci that are closely 
together within a chromosome segment, making it possible to find markers that are 
associated with disease in case-control GWAS analysis 31, 32, 33.  
 GWAS for case-control studies have the issue of optimal selection of cases and 
controls31. Since gray horse melanoma is commonly observed in older horses1,13, controls 
should include horses older than 15 years or likely older, with no melanomas (grade 
zero), to avoid misclassification bias. Case criteria should include the horses with greater 
melanoma grade followed by age; the younger animals with more severe melanomas 
would likely represent the most aggressive type of the disease. Another concern when 
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designing those studies is sample size31. A large number of horses are needed to achieve 
enough power and detect genotypic markers associated with the trait of interest. DNA 
samples are available from 56 gray QH without visible melanomas, from which 22 are 
older than 15 years old.  
 Although GWAS is a powerful technology to identify genotypic markers associated 
with complex disease, a greater number of gray QHs are needed to achieve enough 
power. Another concern when performing GWAS is the presence of population 
stratification that can lead to spurious association, but several statistical tools exist to 
detect and correct for population stratification31.  
 In conclusion, GWAS is a powerful tool to detect regions of the genome associated 
with the trait of interest, but a larger cohort of melanoma cases and controls is needed to 
achieve enough power.     
 
II. Next Generation Sequencing, pooled approach 
 
 An alternative to GWAS is the use of genomic DNA pooling strategy for next 
generation sequencing. This technique is cost effective on estimating difference in allele 
frequency between groups, with a reduced cost. By pooling whole genome samples in 
two different groups (cases and controls) and sequencing them at a high depth of 
coverage, the difference in allele frequency between the pools can be estimated, in 
attempt to identify variants associated with the phenotype of interest. This alternative 
approach pools genomic DNA (non-barcoded) from several individuals and sequences 
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the pool sample. After sequencing, the first objective is to identify all polymorphic sites 
followed by difference in allele frequency between pools. For pooled sequencing, the 
frequency of a variant allele is a function of the population allele frequency and the size 
of the pool 27,28,29,30.  
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